We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

62 hedge funds and large institutions have $13.6M invested in Galectin Therapeutics in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 17

5% more capital invested

Capital invested by funds: $13M → $13.6M (+$656K)

0% more funds holding

Funds holding: 62 → 62 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

56% less call options, than puts

Call options by funds: $76K | Put options by funds: $171K

Holders
62
Holders Change
–
Holders Change %
0%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
20
Reduced
17
Closed
7
Calls
$76K
Puts
$171K
Net Calls
-$95K
Net Calls Change
+$569K

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$1.61M
2
AIG
American International Group
New York
+$578K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$238K
4
BFA
BlackRock Fund Advisors
California
+$61.4K
5
SGAM
Smith Group Asset Management
Texas
+$59.4K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$418K
2
Morgan Stanley
Morgan Stanley
New York
-$287K
3
AFM
Anson Funds Management
Texas
-$195K
4
VKH
Virtu KCG Holdings
New York
-$138K
5
ARTA
A.R.T. Advisors
New York
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$82K +$15.9K +4,450 +22%
Morgan Stanley
27
Morgan Stanley
New York
$67K -$287K -80,223 -80%
Nomura Holdings
28
Nomura Holdings
Japan
$67K +$57.2K +16,000 New
SWP
29
Stratos Wealth Partners
Ohio
$66K – – –
Goldman Sachs
30
Goldman Sachs
New York
$64K +$17.8K +4,996 +36%
Millennium Management
31
Millennium Management
New York
$63K -$19.6K -5,496 -23%
State Board of Administration of Florida Retirement System
32
State Board of Administration of Florida Retirement System
Florida
$61K – – –
Bank of America
33
Bank of America
North Carolina
$60K +$24.9K +6,979 +65%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$59K +$12.1K +3,400 +24%
SGAM
35
Smith Group Asset Management
Texas
$56K +$59.4K +16,634 New
RG
36
Rathbones Group
United Kingdom
$55K – – –
NFA
37
Nationwide Fund Advisors
Ohio
$47K – – –
VOYA Investment Management
38
VOYA Investment Management
Georgia
$46K – – –
PPA
39
Parametric Portfolio Associates
Washington
$46K +$13.3K +3,731 +37%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$34K +$36.4K +10,200 New
BA
41
BlackRock Advisors
Delaware
$31K +$5.83K +1,631 +22%
GT
42
Glenmede Trust
Pennsylvania
$27K – – –
Creative Planning
43
Creative Planning
Kansas
$26K +$536 +150 +2%
Wells Fargo
44
Wells Fargo
California
$16K +$1.22K +340 +8%
Deutsche Bank
45
Deutsche Bank
Germany
$8K -$103K -28,919 -92%
WP
46
WealthPLAN Partners
Nebraska
$8K +$8.93K +2,500 New
Simplex Trading
47
Simplex Trading
Illinois
$7K -$17.3K -4,829 -68%
AllianceBernstein
48
AllianceBernstein
Tennessee
$7K -$714 -200 -9%
UBS Group
49
UBS Group
Switzerland
$6K -$6.81K -1,906 -54%
First Manhattan
50
First Manhattan
New York
$5K – – –
1
2
3

GALT Hedge Fund Activity: Q1 2015 in Review

62 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2015, worth a combined $13.6M — up 5.1% from $13M a quarter earlier.

Fund positioning in GALT was balanced in Q1 2015: 7 funds opened new positions, 7 closed out, 20 added to existing stakes and 17 trimmed.

The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.61M. The largest seller was Susquehanna International Group, cutting an estimated $418K.

  • 62 institutional investors held Galectin Therapeutics (GALT) as of Q1 2015, unchanged from Q4 2014.
  • Funds reported $13.6M of Galectin Therapeutics stock for Q1 2015, up 5.1% quarter-over-quarter.
  • 7 funds opened new Galectin Therapeutics positions in Q1 2015 and 7 closed out, a net change of 0 holders.
  • The largest Galectin Therapeutics buyer in Q1 2015 was Sphera Funds Management, an estimated $1.61M added.
  • The largest Galectin Therapeutics seller in Q1 2015 was Susquehanna International Group, an estimated $418K sold.

Based on aggregated 13F filings for Q1 2015.